linjc16/ctgov huggingface dataset:
Evaluation of a Novel Method of Contrast Volume Quantification - AVERT PLUS

Study Overview
=================
Brief Summary
-----------------
Purpose: To evaluate the accuracy of the AVERT PLUS to monitor contrast volume used during angiographic procedures. Research Design: The AVERT PLUS is an FDA 510K cleared device which consists of a contrast delivery modulator designed to reduce unnecessary contrast dye delivery to the patient during angiography (coronary or peripheral) and a concomitant system to precisely measure contrast volume delivered to the patient. This will be a first in man prospective observational study of the accuracy of this system to quantify contract volume used during clinically indicated angiography in the cardiac catheterization laboratory.

Detailed Description
-----------------
Thirty consecutive subjects who consent to participate and are undergoing planned angiography will be enrolled. The AVERT PLUS is a system which is external to the patient and connected to the control syringe that the physician uses to deliver the contrast dye to the patient. For each injection that the physician performs, the starting syringe volume, the ending syringe volume, and the net contrast delivered to the patient will be recorded. At the same time, the net volume delivered to the patient will also be recorded from the AVERT PLUS console. For each injection, these two sets of variables will be compared to determine accuracy of the AVERT PLUS to quantify net contrast volume used.

Official Title
-----------------
Evaluation of a Novel Method of Contrast Volume Quantification - The AVERT PLUS

Conditions
-----------------
Extravasation of Contrast Media

Intervention / Treatment
-----------------
* Device: AVERT PLUS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: subjects aged 18 or older with cardiovascular disease scheduled to undergo clinically indicated coronary or peripheral angiography who give informed consent to participate. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: AVERT PLUS|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Observational study of the accuracy of this system to quantify contrast volume during a clinical indicated procedure |  | During procedure |
Guided Meditation During Radiotherapy.

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to gather information on the effects of Mindfulness-Based Intervention (MBI) on quality of life during and after radiation treatment. This study involves randomization. There is a 50 percent chance (like a flip of the coin) that you will be randomized to attend meditation sessions during treatment.

Official Title
-----------------
A Randomized Controlled Trial of Guided Mindfulness Intervention During Radiotherapy.

Conditions
-----------------
Quality of Life, Relaxation During Radiation Therapy, Cancer, Radiation Toxicity

Intervention / Treatment
-----------------
* Behavioral: Meditation
* Other: Standard of Care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Prescribed a course of at least 15 daily fractions of RT for curative intent of any malignancy Willing to attend MBI sessions weekly during RT Able to transport themselves to scheduled MBI sessions in the DAHLC Able to complete questionnaire(s) by themselves Native English speaker (MBI sessions, videos, and QOL questionnaires are only available in English) ECOG Performance Status 0-2 Exclusion Criteria: Prescribed a course of RT with fewer than 15 consecutive, daily fractions Unable or unwilling to attend required MBI sessions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Standard of Care<br> | Other: Standard of Care<br>* Patient not assigned to meditation will undergo radiation with usual care and complete quality of life surveys before, during and after treatment.<br>|
| Experimental: Meditation<br> | Behavioral: Meditation<br>* Patients will attend weekly in person guided meditation sessions during the course of their radiation treatment. Patient will complete quality of life surveys before, during and after treatment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effectiveness of Meditation Sessions | including emotional, physical, functional, and social domains assessed via the FACT-G during and after radiotherapy for the treatment of cancer. | Before radiation treatment. | 
| Effectiveness of Meditation Sessions | Comparison of change in total LASA-6 and single question relaxation surveys. | During radiation treatment | 
| Effectiveness of Meditation Sessions | Comparison of change in FACT-G, Promis 10 and LASA-6 surveys. | 3 months and 12 months post radiation treatment. |
Management of Grades 3-5 Renal Trauma in Pediatrics

Study Overview
=================
Brief Summary
-----------------
comparing conservative management versus interventional management in hemodynamically stable paediatric patient with blunt renal trauma, evidence suggests that there is a reduced rate of renal loss and blood transfusion in patients managed conservatively.

Official Title
-----------------
Management of Grades 3-5 Renal Trauma in Pediatrics: A Prospective Case Series

Conditions
-----------------
Renal Trauma

Intervention / Treatment
-----------------
* Other: Surgical


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children ( age group 0-18) who are diagnosed to have renal tissue injury grade 3-5 by contrast CT Exclusion Criteria: Age group more than 18 years Low grade renal trauma 1-2 Patients who get explored due to extra urologic indication without proper urologic assessment

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Conservative group<br> | |
| interventional group<br> | Other: Surgical<br>* Minimal: Such as PCN insertion Endosopic: Such as DJ insertion Surgical: Repair, Partial or total nephrectomy Angioembolization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stabilization of haemodynamic status of the patient in the first 24-72 hours |  | 24 to 72 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resolution of perinephric collection during follow up Triphasic MSCT abdomen and pelvis |  | 1 year |
Identification of Key Blood Molecular Markers for Immunotherapy

Study Overview
=================
Brief Summary
-----------------
To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.

Official Title
-----------------
Identification of Key Blood Molecular Markers for Immunotherapy

Conditions
-----------------
Squamous Cell Carcinoma, Adenocarcinoma, Neoplasms

Intervention / Treatment
-----------------
* Procedure: phlebotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with cancerous tumors based on biopsy or other clinical observations. Patients diagnosed with non-cancerous tumors based on biopsy or other clinical observations. Normal volunteers who do not have cancer or other medical conditions that may affect survival. Exclusion Criteria: Patients will be excluded if, upon clinical observation, they are under a severe septic or inflammatory condition. In these conditions, human body immune response against sepsis or inflammation should be the predominant response, and may shield or block the immune response against tumors. Patients will be excluded if, upon clinical observation, they are under extremely illness situation like myocardial infarction. In such a case, the immune findings may be altered. Patients will be excluded if, upon looking through their medical records, significant information required for data analysis is missing. This is because that patients' medical records will help us connect our research findings with their clinical observations, and further provide guidelines for subsequent treatment options.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: phlebotomy|Standard of care|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To identify and evaluate the presence of pre-existing immunity related markers in peripheral human blood, to identify patients who may respond to IL-12 immunotherapy |  | 3 years |
SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer

Study Overview
=================
Brief Summary
-----------------
In this study, the investigators detected the expression of SREBP1 in thyroid cancer tissues, explored the biological functions of SREBP1 in thyroid cancer cells.

Detailed Description
-----------------
qRT-PCR and immunohistochemistry were used to detect the expression of SREBP1 in 96 pairs thyroid cancer tissues and the adjacent normal tissues. The following methods, including the MTS, colony-forming assay, flow cytometry and hoechst staining were used to detect the biological function of thyroid cancer cells based on SREBP1 interference or not.

Official Title
-----------------
SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer

Conditions
-----------------
Thyroid Cancer

Intervention / Treatment
-----------------
* Other: pathologic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of thyroid cancer Reciving thyroidectomy surgery No experience of radiation therapy Nice treatment compliance and follow-up regularly Exclusion Criteria: Prior history of malignancy ; Radiotherapy history, chemotherapy history; Serious concomitant diseases ; Chronic renal insufficiency and liver dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| thyroid cancer<br>the thyroid cancer was determined by the the Pathology Department based on the pathological evidence. | Other: pathologic<br>* All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.<br>* Other names: radioiodine;|
| the adjacent thyroid tissues<br>the adjacent thyroid tissues was collected from the tissue that 3 centimeters from the thyroid cancer. | Other: pathologic<br>* All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.<br>* Other names: radioiodine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| progression-free survival | disease recurrent of progression | average 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| theraputic efficacy | According to the ATA guideline, patients were divided into four group, including excellent response (ER),indeterminate response (IDR), biochemical incomplete response (BIR), structural incomplete response (SIR) after surgery and radioiodine treatment. | average 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thyroid cancer, SREBP1
Requirement of Propofol for Induction of Unconsciousness in Patients With Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease. The investigators clinical experience showed a trend of delayed emergence among patients undergoing deep brain stimulator (DBS) implantation and pulse generator placement under general anesthesia. Abnormal pharmacodynamics might be present among these patients, which had never been investigated.

Conditions
-----------------
Parkinson's Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Parkinson's disease undergoing deep brain stimulator implantation and pulse generator placement under general anesthesia non-Parkinsonian patients without Parkinson's disease undergoing intracranial surgery under general anesthesia Exclusion Criteria: ASA score higher than Class III predicted difficult airway hearing impairment inability to corporate with instruction alcohol or drug abuser patients refusing to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PD group<br>Patients with Parkinson's disease undergoing deep brain stimulator implantation and pulse generator placement | |
| non-PD group<br>Patients without Parkinson's disease undergoing intracranial surgery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Consciousness status | Consciousness status is evaluated by the observer's assessment of alertness and sedation score (OAA/S). | Participants will be monitored during the period of propofol infusion, an expected average of less than 10 min | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's disease, propofol, deep brain stimulator
Azithromycin in the Treatment of Cryptosporidiosis in Patients Who Have Not Had Success With Other Drugs

Study Overview
=================
Brief Summary
-----------------
To provide azithromycin for the treatment of individual patients with proven cryptosporidiosis whose disease has persisted or progressed despite prior therapies.

Official Title
-----------------
Oral/Intravenous Azithromycin in the Treatment of Cryptosporidiosis in Patients Whose Disease Has Not Been Controlled by Conventional Therapy

Conditions
-----------------
Cryptosporidiosis, HIV Infections

Intervention / Treatment
-----------------
* Drug: Azithromycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: Cryptosporidiosis infection. Life expectancy of at least 1 week. Failed or been intolerant to prior therapy with standard antidiarrheal or antibiotic or other therapies for cryptosporidiosis. Consent of parent or guardian for patients under the legal age of consent. Patients with documented favorable response to azithromycin under Pfizer protocol 066-143 may receive maintenance therapy under this protocol. Patients with persistent diarrhea requiring intravenous (IV) fluid therapy to maintain hydration may receive IV azithromycin after approval by the clinical monitor. Patients whose disease worsens despite a minimum of 2 weeks of oral therapy or patients whose disease shows no improvement after 4 weeks of oral therapy will also be considered for a trial period of intravenous azithromycin. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Known hypersensitivity or significant intolerance to macrolide antibiotics. Eligibility and current treatment at a medical center performing study 066-143, another study of azithromycin for treatment of cryptosporidiosis in AIDS patients. Required: Must have failed or been intolerant to prior therapy with standard antidiarrheal or antibiotic therapies for cryptosporidiosis.

Ages Eligible for Study
-----------------
Minimum Age: 1 Day

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Azithromycin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cryptosporidiosis, Diarrhea, Antidiarrheals, Acquired Immunodeficiency Syndrome, Azithromycin
Evaluation of Self-reported Walking Impairment in Predominantly Illiterate Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the routine feasibility of an image tool adapted from the WELCH questionnaire ( Walking estimated limitation calculated by history) to estimate walking impairment (The WELSH questionnaire: Walking estimated limitation stated by history) in patients investigated for walking impairment. Secondary aims correlation with the maximal walking distance.

Detailed Description
-----------------
The WELSH is self completed by the patients and scored by the physician after self-completion. Patients perform a 6 minutes walking test on a 30m corridor

Official Title
-----------------
The Walking Estimated Limitation Stated by History (WELSH): A Visual Tool to Self-report Walking Impairment From a Predominantly Illiterate Diabetic Population.

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Diagnostic Test: walking ability


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: •Signed consent for the data treatment as a database Exclusion Criteria: Rebuttal to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Interventional Model Description: Prospective cohort
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Diabetic patients<br>Patients referred for the equilibrium or diagnosis of diabetes mellitus will be proposed to participate and estimate their walking ability with the WELSH (Walking estimated limitation stated by History) based solely on images | Diagnostic Test: walking ability<br>* Included patients will perform a 6 min walk test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximal walking distance | Maximal measured distance will be the distance walked during a 6 min walk tests | 10 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
walking impairment, disability, diabetes mellitus
VRQOL in Cataract Patients During the COVID-19 Pandemic

Study Overview
=================
Brief Summary
-----------------
The aim of this questionnaire survey is to evaluate the improvement in vision-related quality of life before and after cataract surgery using the National Eye Institute Visual Function Questionnaire 25 and the delay of improvement in the COVID-19 pandemic.

Official Title
-----------------
Assessment of Vision-related Quality of Life (VRQOL) in Cataract Patients During the COVID-19 Pandemic

Conditions
-----------------
Senile Cataract

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 50 years Senile cataract Indication for unilateral or bilateral cataract surgery Postponed cataract surgery due to the COVID-19 pandemic Signed and dated declaration of consent Exclusion Criteria: Complex form of cataract (traumatic cataract, secondary cataract after intraocular inflammation) Amblyopia on the eye that is to be operated on Severe, visually impairing eye disease on the eye that is to operated on Known dementia or memory problems

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Senile Cataract<br>Patient with senile cataract, whose cataract surgery was postponed in the COVID-19 pandemic | Other: Questionnaire<br>* Patients complete the National Eye Institute Visual Function Questionnaire 25 pre-operative, 1 month and 3 month postoperatively.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement Vision-related quality of life | Extent of improvement of vision-related qualitiy of life due to cataract surgery measured with the National Eye Institut Visual Function Questionnaire 25. | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Delay of Vision-related quality of life | Delay of improvement of vision-related qualitiy of life in the COVID-19 pandemic measured in days between the originally scheduled operation and the actual operation date | 3 months | 
| Visual acuity | Visual acuity difference between visual acuity at the time of indication for cataract surgery, on the day of surgery and one month postoperatively. | 1 month |